Advanced BioDesign is presently seeking additional funding, amounting to €25 million (Series A), to initiate the pivotal Phase II clinical trial in AML and prepare for expansion into solid tumors. This step paves the way for potential partnerships with pharmaceutical companies and a significant exit strategy within the next two years.

The financing provided by Xerys Investis always associated with a strong expertise in the field of company development. This expertise manifests itself by following up the company evolution, listening attentively to the managing team and helping to define the strategic plan.



BPIFrance finances companies – at each stage of their development – through loans, guarantees and equity.

Advanced BioDesign has benefited from the support of BPIFrance and again today through the calls for projects iNov, iDEMO, France Relance, France 2030 of which the company was the winner.